vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-632Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОпыт применения абатацепта у больной ювенильным ревматоидным артритом с вторичной неэффективностью инфликсимабаEXPERIENCE OF TREATMENT WITH ABATACEPT IN CHILD WITH JUVENILE RHEUMATOID ARTHRITIS AND SECONDARY INEFFICIENCY OF INFLIXIMABНикишинаИ.П.NikishinaI.P.neonatepearl@yandex.ruМалиевскийВ.А.MalievskiyV.A.vmalievsky@mail.ruФёдоровЕ.С.FedorovE.S.neonatepearl@yandex.ruПервушинаЕ.П.PervushinaE.P.neonatepearl@yandex.ruНуриахметоваА.Ж.NuriakhmetovaA.Zh.neonatepearl@yandex.ruНаучно-исследовательский институт ревматологии РАМН, МоскваScientific Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowБашкирский государственный медицинский университет, УфаBashkiriya State Medical University, UfaРеспубликанская детская клиническая больница, УфаRepublic Children’s Clinical Hospital, Ufa201116052011103Вопросы современной педиатрии170–174Copyright © Никишина И., Малиевский В., Фёдоров Е., Первушина Е., Нуриахметова А., 20112011Никишина И., Малиевский В., Фёдоров Е., Первушина Е., Нуриахметова А.Nikishina I., Malievskiy V., Fedorov E., Pervushina E., Nuriakhmetova A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/632ReferencesZulian F., Balzarin M., Falcini F. et al. Abatacept for severe Anti-Tumor Necrosis Factor-refractory juvenile idiopathic arthritis related uveitis. Arthr. Care Res. 2010; 62 (6): 821–825.Zulian F., Balzarin M., Falcini F. et al. Abatacept for severe Anti-Tumor Necrosis Factor-refractory juvenile idiopathic arthritis related uveitis. Arthr. Care Res. 2010; 62 (6): 821–825.Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J. Rheumatol. 2008: 35: 1897–1898.Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J. Rheumatol. 2008: 35: 1897–1898.Saurenmann R.K., Levin A.V., Feldman B.M. et al. Risk of new onset uveitis in patients with juvenile idiopathic arthritis treatment with anti–TNF agent. J. Pediatr. 2006: 149: 833–836.Saurenmann R.K., Levin A.V., Feldman B.M. et al. Risk of new onset uveitis in patients with juvenile idiopathic arthritis treatment with anti–TNF agent. J. Pediatr. 2006: 149: 833–836.Foeldvari I., Nielsen S., Kummerle–Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007; 34: 1146–1150.Foeldvari I., Nielsen S., Kummerle–Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007; 34: 1146–1150.Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Ruperto N., Lovell D.J., Li T. et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010; 62 (11): 1542–1551.Ruperto N., Lovell D.J., Li T. et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010; 62 (11): 1542–1551.Ruperto N., Lovell D.J., Quartier P. et al. Longterm safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62 (6): 1792–1802.Ruperto N., Lovell D.J., Quartier P. et al. Longterm safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62 (6): 1792–1802.Ruperto N., Lovell D.J., Cuttica R. et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open label treatment extension. Ann Rheum. Dis. 2010; 69 (4): 718–722.Ruperto N., Lovell D.J., Cuttica R. et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open label treatment extension. Ann Rheum. Dis. 2010; 69 (4): 718–722.
The authors declare that there are no conflicts of interest present.